Data gathered: December 26
AI Stock Analysis - Biomarin Pharmaceutical (BMRN)
Analysis generated October 14, 2024. Powered by Chat GPT.
Biomarin Pharmaceutical Inc. is a prominent biotechnology company that focuses on developing and commercializing innovative biopharmaceuticals for serious and life-threatening rare genetic diseases and conditions. Headquartered in San Rafael, California, Biomarin's portfolio includes a wide array of products that address diverse therapeutic areas such as metabolic disorders and enzyme replacement therapies. Through relentless research and development, the company aims to bring hope to patients and families affected by rare genetic disorders.
Stock Alerts - Biomarin Pharmaceutical (BMRN)
 |
Biomarin Pharmaceutical | December 17 Business Outlook among employees is up by 5.1% over the last month. |
|
Biomarin Pharmaceutical | December 10 Web Traffic is down by 35.2% over the last month. |
|
Biomarin Pharmaceutical | December 9 AI Score is up by 33.1% in the last couple of days. |
|
Biomarin Pharmaceutical | December 5 AI Score is up by 26.8% in the last couple of days. |
Alternative Data for Biomarin Pharmaceutical
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 92 | Sign up | Sign up | Sign up |
| Sentiment | 91 | Sign up | Sign up | Sign up |
| Webpage traffic | 40,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 14 | Sign up | Sign up | Sign up |
| Patents | 75 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 9 | Sign up | Sign up | Sign up |
| Facebook Followers | 6,082 | Sign up | Sign up | Sign up |
| Instagram Followers | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,134 | Sign up | Sign up | Sign up |
| Twitter Mentions | 9 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,810 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 41 | Sign up | Sign up | Sign up |
| Linkedin Employees | 3,321 | Sign up | Sign up | Sign up |
About Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
| Price | $66.63 |
| Target Price | Sign up |
| Volume | 439,030 |
| Market Cap | $12.7B |
| Year Range | $61.93 - $93.84 |
| Dividend Yield | 0% |
| PE Ratio | 40.14 |
| Analyst Rating | 71% buy |
| Industry | Biotechnology |
In the news
 |
Principal Financial Group Inc. Has $32.20 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)December 24 - ETF Daily News |
 |
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-TermDecember 23 - Yahoo |
|
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Rating of “Moderate Buy” from BrokeragesDecember 20 - ETF Daily News |
 |
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?December 18 - Yahoo |
|
National Bank of Canada FI Decreases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)December 18 - ETF Daily News |
 |
Cantor Fitzgerald Reiterates Overweight Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)December 14 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 746M | 188M | 557M | 106M | 119M | 0.550 |
| Q2 '24 | 712M | 130M | 582M | 107M | 135M | 0.560 |
| Q1 '24 | 656M | 125M | 531M | 89M | 123M | 0.460 |
| Q4 '23 | 618M | 135M | 482M | 20M | 41M | 0.180 |
| Q3 '23 | 578M | 128M | 453M | 40M | 61M | 0.210 |
Insider Transactions View All
| Guyer Charles Greg filed to sell 68,909 shares at $66.4. November 14 '24 |
| Burkhart Erin filed to sell 14,449 shares at $90. August 15 '24 |
| Mueller Brian filed to sell 72,159 shares at $75.2. May 31 '24 |
| Davis George Eric filed to sell 56,157 shares at $75.3. May 30 '24 |
| Davis George Eric filed to sell 58,936 shares at $74.5. May 30 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Daniel S. Goldman Democrat |
Apr 17, 23 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
Apr 7, 23 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
Jan 3, 23 | Buy | $1K - $15K |
Read more about Biomarin Pharmaceutical (BMRN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Biomarin Pharmaceutical?
The Market Cap of Biomarin Pharmaceutical is $12.7B.
What is Biomarin Pharmaceutical's PE Ratio?
As of today, Biomarin Pharmaceutical's PE (Price to Earnings) ratio is 40.14.
What is the current stock price of Biomarin Pharmaceutical?
Currently, the price of one share of Biomarin Pharmaceutical stock is $66.63.
How can I analyze the BMRN stock price chart for investment decisions?
The BMRN stock price chart above provides a comprehensive visual representation of Biomarin Pharmaceutical's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biomarin Pharmaceutical shares. Our platform offers an up-to-date BMRN stock price chart, along with technical data analysis and alternative data insights.
Does BMRN offer dividends to its shareholders?
As of our latest update, Biomarin Pharmaceutical (BMRN) does not offer dividends to its shareholders. Investors interested in Biomarin Pharmaceutical should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Biomarin Pharmaceutical?
Some of the similar stocks of Biomarin Pharmaceutical are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.